Patients may choose Zytiga monotherapy to minimize side effects. Prednisone, often used alongside Zytiga, can cause significant weight gain, increased blood sugar, and other adverse effects. Omitting prednisone reduces these risks, potentially improving quality of life.
Some patients experience a better response to Zytiga alone. Clinical trials have shown that some individuals achieve comparable or even superior outcomes without prednisone. Individual responses vary, making monotherapy a viable option in certain cases.
Cost considerations are another factor. Zytiga monotherapy lowers the overall treatment cost. Reducing the medication regimen can lead to significant savings for patients.
Certain health conditions might make the addition of prednisone inadvisable. Patients with diabetes or osteoporosis, for example, might benefit from avoiding the potential exacerbating effects of prednisone.
Important Note: The decision to use Zytiga monotherapy should always be made in consultation with an oncologist. They can assess individual patient factors and determine the best treatment plan.
